Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in East Asian Participants With Overweight or Obesity
NCT05132088Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing oral semaglutide 50 mg once daily with oral semaglutide placebo once daily (2 arms). Primary endpoints: Percent Change From Baseline in Body Weight at 68 weeks and Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to 5% at 68 weeks. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05132088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132088.